Default company panoramic image
08780871 19bd 4b1b a75a a364bda5986f

Ischemix, Inc.

Clinical-stage pharmaceutical company with portfolio of therapeutics for prevention and treatment of serious cardiac and renal conditions.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Maynard, MA, USA
  • Currency USD
  • Founded June 1999
  • Employees 7
  • Website

Company Summary

Ischemix is a privately-held, clinical-phase pharmaceutical company developing a portfolio of therapeutic compounds for the prevention and treatment of serious cardio-renal conditions. There are no currently available therapies for the conditions the Company seeks to treat. Ischemix expects to initially market its lead compound to the critical care area of the hospital.


  • Default avatar
    David DeWahl
    President and Chief Executive Officer

    Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc. Mr. DeWahl is also a co-founder of Life Science Pharmaceuticals, Inc., which is developing novel therapeutics to treat cancer, diabetes and other serious illnesses. Mr. DeWahl was previously an investment banker focused on the health care and life sciences industry


  • Default avatar
    Cooley LLP

Previous Investors

  • Default avatar
    Reinier Beeuwkes PhD
    Default avatar
    Geoffrey Clark MD